David J Schlanger sold $5.9M of PGNY
Executive Chairman at Progyny, Inc.. 156,031 shares at an average of $37.80, traded Dec 26, 2023, filed Dec 28, 2023.
Score components
- +20RoleChair
- +25Trade size$5.9M at market
- +20Share of holdings soldSold 93% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001551306-23-000118, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 26, 2023 | MOption exercise Common Stock10b5-1 | +80,000 | $3.95 | $316k | 168,439 | Dec 28, 2023 |
| Dec 26, 2023 | SOpen-market sale Common Stock10b5-1 | -80,000 | $37.93 | $3.0M | 88,439 | Dec 28, 2023 |
| Dec 27, 2023 | MOption exercise Common Stock10b5-1 | +76,031 | $3.95 | $301k | 164,470 | Dec 28, 2023 |
| Dec 27, 2023 | SOpen-market sale Common Stock10b5-1 | -76,031 | $37.66 | $2.9M | 88,439 | Dec 28, 2023 |
| Dec 26, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -80,000 | $0.00 | $0 | 1,626,053 | Dec 28, 2023 |
| Dec 27, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -76,031 | $0.00 | $0 | 1,550,022 | Dec 28, 2023 |
Related signals
Other insiders at Progyny, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Progyny, Inc. | Allison Swartz EVP, GC | $102k 3,903 shares | -5% | |
| 42Moderate | Progyny, Inc. | Kevin K Gordon director | $312k 11,500 shares | -63% | |
| 42Moderate | Progyny, Inc. | Kevin K Gordon director | $321k 11,500 shares | -63% | |
| 8Weak | Progyny, Inc. | Melissa B Cummings Chief Operating Officer | $71k 2,244 shares | -3% | |
| 25Weak | Progyny, Inc. | Mark S. Livingston CHIEF FINANCIAL OFFICER | $64k 2,517 shares | -3% | |
| 16Weak | Progyny, Inc. | Allison Swartz EVP, GC | $45k 1,798 shares | -2% | |
| 21Weak | Progyny, Inc. | Geoffrey Clapp Chief Product Officer | $39k 1,530 shares | -3% | |
| 17Weak | Progyny, Inc. | Mark S. Livingston CHIEF FINANCIAL OFFICER | $7,310 279 shares | -0% | |
| 37Weak | Progyny, Inc. | Cheryl Scott director | $196k 7,439 shares | -27% | |
| 17Weak | Progyny, Inc. | Allison Swartz EVP, GC | $61k 2,398 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.